Targeting the association of calgranulin B (S100A9) with insulin resistance and type 2 diabetes

详细信息    查看全文

• 作者：Francisco J. Ortega (1)
  Josep M. Mercader (2)
  José M. Moreno-Navarrete (1)
  Mónica Sabater (1)
  Neus Pueyo (1)
  Sergio Valdés (3)
  Bartomeu Ruiz (4)
  Elodie Luche (5)
  Deborah Naon (6)
  Wifredo Ricart (1)
  Patricia Botas (7)
  Elias Delgado (7)
  Remy Burcelin (5)
  Gema Frühbeck (8)
  Fatima Bosch (9)
  Gertrude Mingrone (10)
  Antonio Zorzano (6)
  José M. Fernández-Real (1) (11)
  
• 关键词：Calgranulin B ; Single ; nucleotide polymorphism ; Gene expression ; Muscle ; Adipose tissue ; Innate immune system ; Inflammation ; Obesity ; Insulin resistance ; Type 2 diabetes ; Humans ; Mice
• 刊名：Journal of Molecular Medicine
• 出版年：2013
• 出版时间：April 2013
• 年：2013
• 卷：91
• 期：4
• 页码：523-534
• 全文大小：557KB
• 参考文献：1. Devedjian JC, George M, Casellas A, Pujol A, Visa J, Pelegrin M, Gros L, Bosch F (2000) Transgenic mice overexpressing insulin-like growth factor-II in beta cells develop type 2 diabetes. J Clin Invest 105:731-40 CrossRef
  2. Elbein SC, Hoffman MD, Teng K, Leppert MF, Hasstedt SJ (1999) A genome-wide search for type 2 diabetes susceptibility genes in Utah Caucasians. Diabetes 48:1175-182 CrossRef
  3. Ehrchen JM, Sunderkotter C, Foell D, Vogl T, Roth J (2009) The endogenous Toll-like receptor 4 agonist S100A8/S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer. J Leukoc Biol 86:557-66 CrossRef
  4. Averill MM, Barnhart S, Becker L, Li X, Heinecke JW, Leboeuf RC, Hamerman JA, Sorg C, Kerkhoff C, Bornfeldt KE (2011) S100A9 differentially modifies phenotypic states of neutrophils, macrophages, and dendritic cells: implications for atherosclerosis and adipose tissue inflammation. Circulation 123:1216-226 CrossRef
  5. Catalan V, Gomez-Ambrosi J, Rodriguez A, Ramirez B, Rotellar F, Valenti V, Silva C, Gil MJ, Fernandez-Real JM, Salvador J et al (2011) Increased levels of calprotectin in obesity are related to macrophage content: impact on inflammation and effect of weight loss. Mol Med 17:1157-167 CrossRef
  6. Ortega FJ, Sabater M, Moreno-Navarrete JM, Pueyo N, Botas P, Delgado E, Ricart W, Fruhbeck G, Fernandez-Real JM (2012) Serum and urinary concentrations of calprotectin as markers of insulin resistance and type 2 diabetes. Eur J Endocrinol 167:569-78 CrossRef
  7. Fernandez-Real JM, Pickup JC (2008) Innate immunity, insulin resistance and type 2 diabetes. Trends Endocrinol Metab 19:10-6 CrossRef
  8. Gubern C, Lopez-Bermejo A, Biarnes J, Vendrell J, Ricart W, Fernandez-Real JM (2006) Natural antibiotics and insulin sensitivity: the role of bactericidal/permeability-increasing protein. Diabetes 55:216-24 CrossRef
  9. Lopez-Bermejo A, Chico-Julia B, Castro A, Recasens M, Esteve E, Biarnes J, Casamitjana R, Ricart W, Fernandez-Real JM (2007) Alpha defensins 1, 2, and 3: potential roles in dyslipidemia and vascular dysfunction in humans. Arterioscler Thromb Vasc Biol 27:1166-171 CrossRef
  10. Moreno-Navarrete JM, Martinez-Barricarte R, Catalan V, Sabater M, Gomez-Ambrosi J, Ortega FJ, Ricart W, Bluher M, Fruhbeck G, Rodriguez de Cordoba S et al (2010) Complement factor H is expressed in adipose tissue in association with insulin resistance. Diabetes 59:200-09 CrossRef
  11. Mellbin LG, Hamsten A, Malmberg K, Steffensen R, Ryden L, Ohrvik J, Hansen TK (2010) Mannose-binding lectin genotype and phenotype in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial. Diabetes Care 33:2451-456 CrossRef
  12. Fernandez-Real JM, Valdes S, Manco M, Chico B, Botas P, Campo A, Casamitjana R, Delgado E, Salvador J, Fruhbeck G et al (2010) Surfactant protein d, a marker of lung innate immunity, is positively associated with insulin sensitivity. Diabetes Care 33:847-53 CrossRef
  13. Edgeworth J, Gorman M, Bennett R, Freemont P, Hogg N (1991) Identification of p8,14 as a highly abundant heterodimeric calcium binding protein complex of myeloid cells. J Biol Chem 266:7706-713
  14. Striz I, Trebichavsky I (2004) Calprotectin—a pleiotropic molecule in acute and chronic inflammation. Physiol Res 53:245-53
  15. Ehlermann P, Eggers K, Bierhaus A, Most P, Weichenhan D, Greten J, Nawroth PP, Katus HA, Remppis A (2006) Increased proinflammatory endothelial response to S100A8/A9 after preactivation through advanced glycation end products. Cardiovasc Diabetol 5:6 CrossRef
  16. Foell D, Frosch M, Sorg C, Roth J (2004) Phagocyte-specific calcium-binding S100 proteins as clinical laboratory markers of inflammation. Clin Chim Acta 344:37-1 CrossRef
  17. Mortensen OH, Nielsen AR, Erikstrup C, Plomgaard P, Fischer CP, Krogh-Madsen R, Lindegaard B, Petersen AM, Taudorf S, Pedersen BK (2009) Calprotectin–a novel marker of obesity. PLoS One 4:e7419 CrossRef
  18. Hsu K, Champaiboon C, Guenther BD, Sorenson BS, Khammanivong A, Ross KF, Geczy CL, Herzberg MC (2009) Anti-infective protective properties of S100 calgranulins. Antiinflamm Antiallergy Agents Med Chem 8:290-05
  19. Perera C, McNeil HP, Geczy CL (2010) S100 calgranulins in inflammatory arthritis. Immunol Cell Biol 88:41-9 CrossRef
  20. Newton RA, Hogg N (1998) The human S100 protein MRP-14 is a novel activator of the beta 2 integrin Mac-1 on neutrophils. J Immunol 160:1427-435
  21. Valdes S, Botas P, Delgado E, Alvarez F, Cadorniga FD (2007) Population-based incidence of type 2 diabetes in northern Spain: the Asturias Study. Diabetes Care 30:2258-263 CrossRef
  22. Moreno-Navarrete JM, Ortega FJ, Bassols J, Castro A, Ricart W, Fernandez-Real JM (2008) Association of circulating lactoferrin concentration and 2 nonsynonymous LTF gene polymorphisms with dyslipidemia in men depends on glucose-tolerance status. Clin Chem 54:301-09 CrossRef
  23. Fernandez-Real JM, Mercader JM, Ortega FJ, Moreno-Navarrete JM, Lopez-Romero P, Ricart W (2010) Transferrin receptor-1 gene polymorphisms are associated with type 2 diabetes. Eur J Clin Invest 40:600-07 CrossRef
  24. Bonora E, Targher G, Alberiche M, Bonadonna RC, Saggiani F, Zenere MB, Monauni T, Muggeo M (2000) Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 23:57-3 CrossRef
  25. Moreno-Navarrete JM, Ortega FJ, Rodriguez-Hermosa JI, Sabater M, Pardo G, Ricart W, Fernandez-Real JM (2011) OCT1 Expression in adipocytes could contribute to increased metformin action in obese subjects. Diabetes 60:168-76 CrossRef
  26. Cani PD, Knauf C, Iglesias MA, Drucker DJ, Delzenne NM, Burcelin R (2006) Improvement of glucose tolerance and hepatic insulin sensitivity by oligofructose requires a functional glucagon-like peptide 1 receptor. Diabetes 55:1484-490 CrossRef
  27. Gauderman WJ (2002) Sample size requirements for association studies of gene-gene interaction. Am J Epidemiol 155:478-84 CrossRef
  28. Leclerc E, Fritz G, Vetter SW, Heizmann CW (2009) Binding of S100 proteins to RAGE: an update. Biochim Biophys Acta 1793:993-007 CrossRef
  29. Fischer M, Timper K, Radimerski T, Dembinski K, Frey DM, Zulewski H, Keller U, Muller B, Christ-Crain M, Grisouard J (2010) Metformin induces glucose uptake in human preadipocyte-derived adipocytes from various fat depots. Diabetes Obes Metab 12:356-59 CrossRef
  30. Alexandre KB, Smit AM, Gray IP, Crowther NJ (2008) Metformin inhibits intracellular lipid accumulation in the murine pre-adipocyte cell line, 3T3-L1. Diabetes Obes Metab 10:688-90 CrossRef
  31. Yang RZ, Lee MJ, Hu H, Pray J, Wu HB, Hansen BC, Shuldiner AR, Fried SK, McLenithan JC, Gong DW (2006) Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action. Am J Physiol Endocrinol Metab 290:E1253–E1261 CrossRef
  32. Marenholz I, Heizmann CW, Fritz G (2004) S100 proteins in mouse and man: from evolution to function and pathology (including an update of the nomenclature). Biochem Biophys Res Commun 322:1111-122 CrossRef
  33. Herder C, Zierer A, Koenig W, Roden M, Meisinger C, Thorand B (2009) Transforming growth factor-beta1 and incident type 2 diabetes: results from the MONICA/KORA case-cohort study, 1984-002. Diabetes Care 32:1921-923 CrossRef
  34. Lim SY, Raftery MJ, Goyette J, Hsu K, Geczy CL (2009) Oxidative modifications of S100 proteins: functional regulation by redox. J Leukoc Biol 86:577-87 CrossRef
  
• 作者单位：Francisco J. Ortega (1)
  Josep M. Mercader (2)
  José M. Moreno-Navarrete (1)
  Mónica Sabater (1)
  Neus Pueyo (1)
  Sergio Valdés (3)
  Bartomeu Ruiz (4)
  Elodie Luche (5)
  Deborah Naon (6)
  Wifredo Ricart (1)
  Patricia Botas (7)
  Elias Delgado (7)
  Remy Burcelin (5)
  Gema Frühbeck (8)
  Fatima Bosch (9)
  Gertrude Mingrone (10)
  Antonio Zorzano (6)
  José M. Fernández-Real (1) (11)
  
  1. Department of Diabetes, Endocrinology and Nutrition (UDEN), Institut d’Investigació Biomédica de Girona (IdIBGi), CIBER de la Fisiopatología de la Obesidad y la Nutrición (CIBERobn, CB06/03/0010) and Instituto de Salud Carlos III (ISCIII), Girona, Spain
  2. Joint IRB-BSC Program on Computational Biology, Barcelona Supercomputing Center, Barcelona, Spain
  3. Service of Endocrinology and Nutrition, Hospital Universitario Carlos Haya, CIBER of Diabetes and Metabolism (CIBERdem, CB07/08) and Instituto de Salud Carlos III (ISCIII), Málaga, Spain
  4. Department of Surgery, Institut d’Investigació Biomédica de Girona (IdIBGi), Girona, Spain
  5. INSERM Unité 858, Institut de Médecine Moléculaire de Rangueil, Université Paul Sabatier, IFR31, Toulouse, France
  6. Departament de Bioquímica i Biología Molecular, Facultat de Biología, Universitat de Barcelona, Institute for Research in Biomedicine (IRB Barcelona), CIBER of Diabetes and Metabolism (CIBERdem, CB07/08) and Instituto de Salud Carlos III (ISCIII), Barcelona, Spain
  7. Hospital Central de Asturias, Oviedo, Spain
  8. Clínica Universitaria de Navarra, CIBER de la Fisiopatología de la Obesidad y la Nutrición (CIBERobn, CB06/03/0010) and Instituto de Salud Carlos III (ISCIII), Pamplona, Spain
  9. Center of Animal Biotechnology and Gene Therapy (CBATEG), Universitat Autònoma de Barcelona, Bellaterra, Spain
  10. Institute of Internal Medicine, Catholic University of Rome, Rome, Italy
  11. Section of Diabetes, Endocrinology and Nutrition, Hospital of Girona “Dr Josep Trueta-Carretera de Fran?a s/n, 17007, Girona, Spain
  
• ISSN：1432-1440

文摘

Calgranulin B (S100A9) was recognized as a candidate type 2 diabetes (T2D) gene in the genomic profiling of muscle from a rodent model of T2D and identifying the human orthologs of genes localized in T2D susceptibility regions. Circulating and S100A9 expressions in muscle and adipose tissue, isolated fat cells, and mouse models were evaluated. A common 5-upstream single-nucleotide polymorphism (SNP; rs3014866) for S100A9 was analyzed, as well as the effects of weight loss and treatments in vitro with recombinant S100A9. S100a9 expression was increased in muscle of diabetic mice (1.6-fold, p--.002), and in muscle from subjects with impaired glucose tolerance (?-fold, p--.028; n--4). The rs3014866 SNP was associated with circulating S100A9 and the risk of T2D, having TT carriers at 28?% (p--.03) lower risk (n--,450). Indeed, increased circulating S100A9 (?-fold, p--.03; n--06) and subcutaneous (2-fold, p--.01) and omental (1.4-fold, p--.04) S100A9 gene expressions (n--3) in TT carriers run in parallel to decreased fasting glucose and glycated hemoglobin. Accordingly, metformin led to increased S100A9 mRNA in ex vivo-treated adipose tissue explants (n--/treatment). Otherwise, obese subjects showed a compensatory increase in circulating and S100A9 expressions in adipose (n--26), as further demonstrated by decreased levels after diet- (?4?%, p--.002; n--0) and surgery-induced (?8?%, p--.02; n--) weight loss. Lipopolysaccharide led to increased S100A9 in adipose from mice (n--/treatment) while recombinant S100A9 downregulated inflammation in adipocytes (n--/treatment). Current findings support the strategy of testing differentially expressed genes in mice and human orthologs associated with T2D. The increased S100A9 reported for obesity and insulin resistance may be envisioned as a compensatory mechanism for inflammation.